By staff writers

June 14, 2012 -- Echocardiography technology developer VentriPoint said that the Mayo Clinic will participate in a multicenter clinical trial to evaluate the firm's VMS ultrasound diagnostic tool in patients with pulmonary arterial hypertension (PAH).

The company said it's currently pursuing U.S. Food and Drug Administration (FDA) 510(k) clearance for VMS. The tool is cleared for sale and clinical use in Canada and Europe, VentriPoint said.

Copyright © 2012

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking